Figure 1.

S1P anabolism attenuate prognosis for BCA patients. A, The illustration of S1P production and the involved enzyme (Sphk1 and Sphk2). SS: sphingosine; SPHK 1/2: sphingosine kinase 1/2; SGPP1/2: Sphingosine‐1‐phosphate phosphatase 1/2; S1P: Sphingosine‐1‐phosphate; SGPL1: Sphingosine‐1‐phosphate lyase1; LPP 1/2/3: lipid phosphate phosphatases 1/2/3; HDC: Hexadecenal; ELP: Ethanolamine phosphate; S1PR1/2/3/4/5: Sphingosine‐1‐phosphate receptor 12/3/4/5. B, HR score to evaluate the impact of S1P anabolism in BCA prognosis. The items on the right are the patient classification for KM plotter analyses. C‐E, Kaplan‐Meier plot survival analysis of SPHK2 in overall patients (C), basal cell type (D), and patients with adjuvant therapy (E). In X‐axis is survival of observe patients, Y‐axis is observed time for 10 years. The words low and high means the target gene expression was low or high in patients. Number at risk means the observe number of patients